The effect of single dose of ketamine injection in reducing suicidal ideation in type 1 bipolardisorder patients in the depressive phase

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141209020258N182

Enrollment

124

Registered

2023-05-07

Start date

2023-05-20

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 1 bipolardisorder patients in the depressive phase. Mood disorder due to known physiological condition with depressive features

Interventions

Intervention 1: Intervention group: They will receive intravenous ketamine (0.5 mg for every kilogram of intravenous ketamine over 30 minutes). Intervention 2: Control group: normal saline (500 millil

Eligibility

Sex/Gender

All

Age

15 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with bipolar disorder type 1 in the depressive phase according to DSM5 criteria and having suicidal thoughts No drug use in the last month. Not receiving electric shock during the last month and during recent hospitalization. 15 to 65 years No mental retardation Absence of underlying disease No history of stroke, seizure, brain tumor, dementia and being in delirium phase No history of head injury and loss of consciousness Not using all kinds of drugs and alcohol in the past month

Exclusion criteria

Exclusion criteria: Lack of consent of the patient or guardian to participate in the study Drug sensitivity

Design outcomes

Primary

Measure	Time frame
Suicidal ideation. Timepoint: Start of the study, 2, 24 and 72 hours after the start of the study. Method of measurement: Beck Suicidal Ideation Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Alireza Kamali

Arak University of Medical Sciences

alikamaliir@yahoo.com+98 68 3222 2003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026